Literature DB >> 15507603

Identification and characterization of persistent human erythrovirus infection in blood donor samples.

Daniel Candotti1, Nermin Etiz, Armen Parsyan, Jean-Pierre Allain.   

Abstract

The presence of human erythrovirus DNA in 2,440 blood donations from the United Kingdom and sub-Saharan Africa (Ghana, Malawi, and South Africa) was screened. Sensitive qualitative and real-time quantitative PCR assays revealed a higher prevalence of persistent infection with the simultaneous presence of immunoglobulin G (IgG) and viral DNA (0.55 to 1.3%) than previously reported. This condition was characterized by a low viral load (median, 558 IU/ml; range, 42 to 135,000 IU/ml), antibody-complexed virus, free specific IgG, and potentially infectious free virus. Human erythrovirus genotype 1 (formerly parvovirus B19) was prevalent in the United Kingdom, Malawi, and South Africa. In contrast, only human erythrovirus genotype 3 (erythrovirus variant V9) was prevalent in Ghana. Genotype 3 had considerable genetic diversity, clustering in two probable subtypes. Genotype 1-based antibody assays failed to detect 38.5% of Ghanaian samples containing antibodies to genotype 3 virus but did not fail to detect cases of persistent infection. This study indicates a potential African origin of genotype 3 human erythrovirus and considerable shortcomings in the tools currently used to diagnose erythrovirus infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507603      PMCID: PMC525065          DOI: 10.1128/JVI.78.22.12169-12178.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies.

Authors:  H Sato; J Hirata; N Kuroda; H Shiraki; Y Maeda; K Okochi
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

2.  Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.

Authors:  T Saikawa; S Anderson; M Momoeda; S Kajigaya; N S Young
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  The prevalence of antibody to human parvovirus B19 in England and Wales.

Authors:  B J Cohen; M M Buckley
Journal:  J Med Microbiol       Date:  1988-02       Impact factor: 2.472

4.  Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction.

Authors:  F McOmish; P L Yap; A Jordan; H Hart; B J Cohen; P Simmonds
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

5.  Primary and secondary infection with human parvovirus B19 in pregnant women in South Africa.

Authors:  B D Schoub; N K Blackburn; S Johnson; J M McAnerney
Journal:  S Afr Med J       Date:  1993-07

6.  Immune response to B19 parvovirus and an antibody defect in persistent viral infection.

Authors:  G J Kurtzman; B J Cohen; A M Field; R Oseas; R M Blaese; N S Young
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

7.  Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19.

Authors:  M Söderlund; C S Brown; W J Spaan; L Hedman; K Hedman
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

8.  Quantification of parvovirus B19 DNA using COBAS AmpliPrep automated sample preparation and LightCycler real-time PCR.

Authors:  Stefan Schorling; Gunnar Schalasta; Gisela Enders; Michael Zauke
Journal:  J Mol Diagn       Date:  2004-02       Impact factor: 5.568

9.  Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests.

Authors:  Kati Hokynar; Päivi Norja; Harri Laitinen; Pekka Palomäki; Antoine Garbarg-Chenon; Annamari Ranki; Klaus Hedman; Maria Söderlund-Venermo
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

10.  Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1.

Authors:  Daniel Candotti; Jillian Temple; Shirley Owusu-Ofori; Jean-Pierre Allain
Journal:  J Virol Methods       Date:  2004-06-01       Impact factor: 2.014

View more
  43 in total

1.  Evidence of serological cross-reactivity between genotype 1 and genotype 3 erythrovirus infections.

Authors:  Amanda Corcoran; Sean Doyle; Jean-Pierre Allain; Daniel Candotti; Armen Parsyan
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Biological and immunological relations among human parvovirus B19 genotypes 1 to 3.

Authors:  Anna Ekman; Kati Hokynar; Laura Kakkola; Kalle Kantola; Lea Hedman; Heidi Bondén; Matthias Gessner; Claudia Aberham; Päivi Norja; Simo Miettinen; Klaus Hedman; Maria Söderlund-Venermo
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

3.  Molecular characterization of human parvovirus B19 genotypes 2 and 3.

Authors:  Zhaojun Chen; Wuxiang Guan; Fang Cheng; Aaron Yun Chen; Jianming Qiu
Journal:  Virology       Date:  2009-09-15       Impact factor: 3.616

Review 4.  Simian parvoviruses: biology and implications for research.

Authors:  Meredith A Simon
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

5.  Virus detection and semiquantitation in explanted heart tissues of idiopathic dilated cardiomyopathy adult patients by use of PCR coupled with mass spectrometry analysis.

Authors:  Yohan Nguyen; Fanny Renois; Nicolas Leveque; Delphine Giusti; Marcus Picard-Maureau; Patrick Bruneval; Paul Fornes; Laurent Andreoletti
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

6.  Parvovirus B19 - Revised.

Authors:  Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

Review 7.  Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Gabriele Calizzani; Fabio Candura; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

8.  Parvovirus B19 Passive Transmission by Transfusion of Intercept® Blood System-Treated Platelet Concentrate.

Authors:  Peter Gowland; Stefano Fontana; Martin Stolz; Nicola Andina; Christoph Niederhauser
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

9.  Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue.

Authors:  Päivi Norja; Kati Hokynar; Leena-Maija Aaltonen; Renwei Chen; Annamari Ranki; Esa K Partio; Olli Kiviluoto; Irja Davidkin; Tomi Leivo; Anna Maria Eis-Hübinger; Beate Schneider; Hans-Peter Fischer; René Tolba; Olli Vapalahti; Antti Vaheri; Maria Söderlund-Venermo; Klaus Hedman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

10.  Parvovirus B19 infection and severe anaemia in Kenyan children: a retrospective case control study.

Authors:  James Wildig; Yvonne Cossart; Norbert Peshu; Nimmo Gicheru; James Tuju; Thomas N Williams; Charles R Newton
Journal:  BMC Infect Dis       Date:  2010-04-03       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.